Interferon-alpha and interleukin-2 in the treatment of renal cell cancer.
Holdener
E E
EE
Department of Preclinical Research, F. Hoffmann-Laroche & Co., Basel, Switzerland.
Emmons
R P
RP
Brunda
M
M
Evans
L
L
Levitt
D
D
D000818:Animals; D002292:Carcinoma, Renal Cell / Q000601:surgery / Q000628:therapy*; D003131:Combined Modality Therapy; D004354:Drug Screening Assays, Antitumor; D004357:Drug Synergism; D006801:Humans; D007155:Immunologic Factors / Q000627:therapeutic use*; D007370:Interferon Type I / Q000008:administration & dosage / Q000627:therapeutic use*; D007376:Interleukin-2 / Q000008:administration & dosage / Q000627:therapeutic use*; D007680:Kidney Neoplasms / Q000601:surgery / Q000628:therapy*; D051379:Mice; D016032:Randomized Controlled Trials as Topic; D011994:Recombinant Proteins
D007155:Immunologic Factors; D007370:Interferon Type I; D007376:Interleukin-2; D011994:Recombinant Proteins